CN111603458A - A composition for treating ovarian cancer - Google Patents

A composition for treating ovarian cancer Download PDF

Info

Publication number
CN111603458A
CN111603458A CN202010588394.2A CN202010588394A CN111603458A CN 111603458 A CN111603458 A CN 111603458A CN 202010588394 A CN202010588394 A CN 202010588394A CN 111603458 A CN111603458 A CN 111603458A
Authority
CN
China
Prior art keywords
ovarian cancer
composition
parts
cyclophosphamide
traditional chinese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010588394.2A
Other languages
Chinese (zh)
Other versions
CN111603458B (en
Inventor
李�荣
许时丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Second Hospital University Of South China
Original Assignee
Second Hospital University Of South China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Hospital University Of South China filed Critical Second Hospital University Of South China
Priority to CN202010588394.2A priority Critical patent/CN111603458B/en
Publication of CN111603458A publication Critical patent/CN111603458A/en
Application granted granted Critical
Publication of CN111603458B publication Critical patent/CN111603458B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998—Hordeum (barley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a composition for treating ovarian cancer, which belongs to the field of antitumor drugs and is prepared from raw materials including lycopene cis-isomer with the mass ratio of 1:8-10:20-40, cyclophosphamide and traditional Chinese medicine extract, wherein the traditional Chinese medicine extract is any one or a mixture of more of frankincense, saffron, myrrh, black nightshade, turmeric, golden cypress, leech, endothelium corneum gigeriae galli, angelica and charred triplet. The invention combines lycopene and cyclophosphamide, improves the sensitivity of tumor cells to cyclophosphamide, thereby improving the killing effect of cyclophosphamide on ovarian tumor cells, further selects the traditional Chinese medicine components for strengthening body resistance and consolidating the constitution, reducing swelling and clearing heat, and promoting blood circulation and removing blood stasis, and combines the active components, thereby enhancing the effect of lycopene and cyclophosphamide. Has the characteristics of quick response and obvious effect.

Description

A composition for treating ovarian cancer
Technical Field
The invention relates to a pharmaceutical composition, in particular to a composition for treating ovarian cancer, and belongs to the field of antitumor drugs.
Background
Ovarian cancer is a common malignant tumor in women, and the mortality rate of ovarian cancer is the first mortality rate caused by female tumors. Because the early stage of ovarian cancer lacks obvious external symptoms, the condition of the ovarian cancer is hidden, and missed diagnosis is easy to cause. Metastasis already occurs when most ovarian cancer patients are diagnosed, and the tumor focus is difficult to completely remove by simple surgical treatment, so that postoperative recurrence is easy to occur. Over 70% of patients have been diagnosed with advanced stages and about 70% relapse within two years after surgery.
Drug therapy is an auxiliary means for ovarian cancer surgical treatment, and the primary therapeutic drugs mainly use alkylating agents, including cyclophosphamide. With the development of new drugs, platinum, gemcitabine, docetaxel, etoposide, paclitaxel, etc. are also gradually used for the treatment of ovarian cancer. However, clinical practice proves that the curative effect of single chemotherapeutic drugs on ovarian cancer is not ideal, so that the combined administration scheme becomes the main treatment scheme of clinical ovarian cancer. Such as cyclophosphamide, cisplatin combinations, paclitaxel and cisplatin combinations, and the like. The anti-ovarian cancer drugs currently being researched mainly comprise targeted small molecule drugs. In addition, in the use of chemotherapy drugs, the ovarian cancer is easy to have drug resistance, so that the tumor cells lose sensitivity to the chemotherapy drugs and the curative effect of the drugs is reduced.
Ovarian cancer is rather similar to the history of "ovarian cyst" in ancient TCM. The pathogenesis of the disease is related to qi stagnation, blood stasis and phlegm dampness and blood stasis, so the treatment methods of regulating qi, activating blood circulation and softening hardness and dissipating stagnation are adopted all the time. The invention considers that although the clinical symptoms of ovarian cancer are accompanied by pathogenic excess and healthy qi deficiency, pathogenic toxin is accumulated in the heat, and the symptoms are the basis. Although the deficiency of qi and blood is shown in the later stage of the onset of disease and is also the result of impairment of healthy qi due to heat-toxin, the existing traditional Chinese medicine treatment has some obvious defects: firstly, the treatment effect is not obvious enough; secondly, the effect is slow.
At present, no report about the combination of traditional Chinese medicines and western medicines for treating ovarian cancer is found.
Disclosure of Invention
In view of the above, the invention provides a composition for treating ovarian cancer, which solves the problems of insufficient obvious effect, delayed effect and easy recurrence in the previous ovarian cancer treatment.
In order to achieve the purpose, the invention adopts the following technical scheme:
a composition for treating ovarian cancer comprises lycopene cis-isomer, cyclophosphamide and Chinese medicinal extract at a mass ratio of 1:8-10: 20-40;
the Chinese medicinal extract is one or more of Olibanum, stigma croci Sativi, Myrrha, herba Solani Nigri, Curcuma rhizome, cortex Phellodendri, Hirudo, endothelium corneum Gigeriae Galli, radix Angelicae sinensis, and charred triplet.
Further, raw materials for preparing the composition comprise a lycopene cis-isomer, cyclophosphamide and a traditional Chinese medicine extract in a mass ratio of 1:8: 40.
Further, raw materials for preparing the composition comprise a lycopene cis-isomer, cyclophosphamide and a traditional Chinese medicine extract in a mass ratio of 1:10: 35.
Further, the traditional Chinese medicine extract is prepared from the following raw materials in parts by weight: 6-38 parts of frankincense, 6-10 parts of saffron, 5-35 parts of myrrh, 5-32 parts of black nightshade, 5-15 parts of turmeric, 5-15 parts of golden cypress, 5-7 parts of leech, 5-10 parts of chicken's gizzard-membrane, 4-30 parts of angelica and 4-9 parts of charred triplet.
Further, the traditional Chinese medicine extract is a mixture of extract fine powder prepared by respectively crushing the raw materials and extracting the raw materials by a conventional water extraction process.
Further, the pharmaceutic adjuvant comprises any one or a mixture of more of an adsorbent, an adhesive, a solvent and a wetting agent, wherein the adsorbent is calcium hydrophosphate or microcrystalline cellulose, the adhesive is medicinal starch, the wetting agent is ethanol, glycerol or tween-80, and the solvent is purified water.
The Lycopene has the beneficial effects that the Lycopene (Lycopene, Lyp) has the physiological functions of quenching active oxygen, eliminating free radicals of a human body, preventing heart disease, slowing down atherosclerosis, preventing various cancers, resisting aging, protecting skin and the like. Epidemiological studies have shown that Lyp concentrations in blood are inversely correlated with the incidence of various cancers. Lyp can reduce the activity of the mitogen of breast cancer cells, inhibit the cell cycle from being arrested in the stage from G1 to S, enhance the function of intercellular junction communication (GJIC), promote the interaction between phagocytes and lymphocytes, activate the cells by secreting cell activating factors, finally express the promotion of phagocytic capacity and lymphocyte transformation, enhance the immune function and further induce the apoptosis of tumor cells.
Cyclophosphamide (CTX) is a nitrogen mustard derivative which enters a human body and is hydrolyzed by an excessive amount of phosphoramidase or phosphatase present in the liver or tumor to become activated phosphoramide. The antineoplastic spectrum is wide, is the first so-called 'latent' broad-spectrum antineoplastic drug and is effective to leukemia and solid tumors.
The invention selects the cis isomer of lycopene through experiments, combines the lycopene and the cyclophosphamide, improves the sensitivity of tumor cells to the cyclophosphamide, thereby improving the killing effect of the cyclophosphamide on ovarian tumor cells, and further combines the traditional Chinese medicine components for strengthening body resistance and consolidating the constitution, reducing swelling and clearing heat, and promoting blood circulation and removing blood stasis with the active components, thereby enhancing the effect of the lycopene and the cyclophosphamide. Has the characteristics of quick response and obvious effect.
The traditional Chinese medicine components related by the invention have the following effects:
frankincense, radix astragali, rhizoma arisaematis, radix astragali.
Saffron, neutral in nature and sweet in taste, enters heart and liver meridians, and has the effects of promoting blood circulation to remove blood stasis, cooling blood and removing toxicity, and relieving depression and tranquilizing mind.
Myrrh, mild in nature, pungent and bitter in flavor, enters heart, liver and spleen channels, removes stasis and relieves pain, and diminishes swelling and promotes granulation.
Solanum nigrum, cold in nature, bitter in taste, non-toxic, heat-clearing, detoxifying, blood circulation-promoting and swelling-reducing.
Turmeric, with warm nature and pungent and bitter taste, enters spleen and liver meridians, breaks blood and activates qi, and clears meridians to stop pain.
Phellodendron bark, cortex Phellodendri, with cold nature and bitter taste, enters kidney and bladder meridians, clears heat and dries dampness, purges fire and removes steam, detoxifies and cures sores.
Leeches, with mild nature, salty and bitter taste, enter liver meridian, break blood and dredge meridians, remove blood stasis and eliminate stasis.
Endothelium corneum Gigeriae Galli, neutral in nature and sweet in flavor, enters spleen, stomach, small intestine and bladder channels, and has effects of invigorating stomach, resolving food stagnation, astringing seminal emission, relieving enuresis, and treating stranguria and removing calculus.
Chinese angelica root, radix Angelicae sinensis, warm in nature, sweet and pungent in flavor, enters liver, heart and spleen channels, and has the effects of enriching and activating blood, regulating menstruation, relieving pain, moistening intestines and relaxing bowels.
The charred triplet, namely charred malt, charred hawthorn fruit and charred medicated leaven, has good functions of removing food retention and resolving stagnation, but has different characteristics, and is used together for promoting digestion, removing stagnation and strengthening and transporting spleen and stomach.
The invention also provides application of the composition for treating ovarian cancer in preparation of ovarian cancer quality medicines.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the following examples, the raw materials and reagents involved meet the criteria set by pharmacopoeia, as well as the safety and formulation requirements.
Example 1
The composition for treating ovarian cancer is prepared by respectively crushing and extracting frankincense 6g, saffron 6g, myrrh 5g, black nightshade 5g, turmeric 5g, phellodendron bark 5g, leech 5g, chicken's gizzard-skin 5g, angelica 4g and charred triplet 4g with water to prepare extract fine powder, mixing to obtain a traditional Chinese medicine extract, and mixing the lycopene cis-isomer, cyclophosphamide and the traditional Chinese medicine extract according to a mass ratio of 1:8: 20.
Example 2
The composition for treating ovarian cancer is prepared by respectively crushing 38g of frankincense, 10g of saffron, 35g of myrrh, 32g of black nightshade, 15g of turmeric, 15g of golden cypress, 7g of leech, 10g of chicken's gizzard-membrane, 30g of Chinese angelica and 9g of charred triplet, extracting with water to prepare extract fine powder, mixing to obtain a traditional Chinese medicine extract, and mixing the lycopene cis-isomer, cyclophosphamide and the traditional Chinese medicine extract according to the mass ratio of 1:8: 40.
Example 3
The composition for treating ovarian cancer is prepared by respectively crushing 30g of frankincense, 10g of saffron, 20g of myrrh, 10g of black nightshade, 10g of turmeric, 10g of golden cypress, 6g of leech, 5g of chicken's gizzard-membrane, 15g of Chinese angelica and 5g of charred triplet, extracting with water to prepare extract fine powder, mixing to obtain a traditional Chinese medicine extract, and mixing the lycopene cis-isomer, cyclophosphamide and the traditional Chinese medicine extract according to the mass ratio of 1:10: 30.
Example 4
The composition for treating ovarian cancer is prepared by respectively crushing and extracting frankincense 20g, saffron 10g, myrrh 20g, black nightshade 20g, turmeric 10g, golden cypress 10g, leech 6g, chicken's gizzard-membrane 5g, Chinese angelica 5g and charred triplet 4g with water to prepare extract fine powder, mixing to obtain a traditional Chinese medicine extract, and mixing the lycopene cis-isomer, cyclophosphamide and the traditional Chinese medicine extract according to a mass ratio of 1:8: 40.
Example 5
The composition for treating ovarian cancer is prepared by respectively crushing and extracting frankincense 30g, saffron 8g, myrrh 25g, black nightshade 25g, turmeric 10g, golden cypress 15g, leech 5g, chicken's gizzard-membrane 5g, Chinese angelica 20g and charred triplet 5g with water to prepare extract fine powder, mixing to obtain a traditional Chinese medicine extract, and mixing the lycopene cis-isomer, cyclophosphamide and the traditional Chinese medicine extract according to the mass ratio of 1:10: 35.
Clinical case statistics
Adding microcrystalline cellulose, medicinal starch, glycerol and purified water into the composition for treating ovarian cancer in the above examples 1-4 respectively to prepare oral tablets, which are marked as tablets 1-4 respectively;
the tablets 1-4 are clinical medicines for 20 patients with ovarian cancer respectively, and 20 patients are all patients with middle and advanced stage ovarian cancer, wherein 9 patients are treated by operation and are not cured.
In 20 patients, tablets 1 to 4 of the above examples 1 to 4 were taken in a targeted manner according to the onset and the degree of onset (the sum of the mass ratios of the cis-isomer of lycopene and cyclophosphamide is appropriately increased in patients with severe diseases), and the curative effect after 2 courses of treatment (60 days) was counted as follows:
item Early stage of the process Middle stage Late stage Total of Ratio of
Basic healing 3 5 1 9 45％
Improvement of life 2 3 2 7 35％
Invalidation 0 3 1 4 20％
Total of 5 11 4 20 100％
The curative effect standard is as follows:
the basic cure is as follows: after the medicine is taken, tumor cells are removed, and the medicine has no symptoms such as pain or bleeding and can automatically and normally move;
improvement: the clinical symptoms are better than those before the administration, and the symptoms are basically controlled;
and (4) invalidation: the symptoms are not obviously different before and after the administration.
The effective rate of the invention reaches 80%, the cure rate reaches 45%, and no toxic or side effect occurs.

Claims (8)

1. A composition for treating ovarian cancer is characterized in that raw materials for preparing the composition comprise a cis-isomer of lycopene, cyclophosphamide and a traditional Chinese medicine extract in a mass ratio of 1:8-10: 20-40;
the Chinese medicinal extract is one or more of Olibanum, stigma croci Sativi, Myrrha, herba Solani Nigri, Curcuma rhizome, cortex Phellodendri, Hirudo, endothelium corneum Gigeriae Galli, radix Angelicae sinensis, and charred triplet.
2. The composition for treating ovarian cancer according to claim 1, wherein raw materials for preparing the composition comprise the cis-isomer of lycopene, cyclophosphamide and traditional Chinese medicine extract in a mass ratio of 1:8: 40.
3. The composition for treating ovarian cancer according to claim 1, wherein the raw materials for preparing the composition comprise the cis-isomer of lycopene, cyclophosphamide and traditional Chinese medicine extract in a mass ratio of 1:10: 35.
4. The composition for treating ovarian cancer according to claim 1, wherein the traditional Chinese medicine extract is prepared from the following raw materials in parts by weight: 6-38 parts of frankincense, 6-10 parts of saffron, 5-35 parts of myrrh, 5-32 parts of black nightshade, 5-15 parts of turmeric, 5-15 parts of golden cypress, 5-7 parts of leech, 5-10 parts of chicken's gizzard-membrane, 4-30 parts of angelica and 4-9 parts of charred triplet.
5. The composition for treating ovarian cancer according to claim 1 or 4, wherein the traditional Chinese medicine extract is a mixture of extract fine powder prepared by respectively crushing raw materials and extracting the raw materials by a conventional water extraction process.
6. The composition for treating ovarian cancer according to claim 1, further comprising a pharmaceutical adjuvant, wherein the pharmaceutical adjuvant comprises any one or a mixture of several of an adsorbent, a binder, a solvent and a wetting agent.
7. The composition for treating ovarian cancer according to claim 6, wherein the adsorbent is calcium hydrogen phosphate or microcrystalline cellulose, the binder is medicinal starch, the wetting agent is ethanol, glycerol or Tween-80, and the solvent is purified water.
8. Use of a composition according to any one of claims 1 to 7 for the treatment of ovarian cancer in the manufacture of a medicament for the treatment of ovarian cancer.
CN202010588394.2A 2020-06-24 2020-06-24 A composition for treating ovarian cancer Active CN111603458B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010588394.2A CN111603458B (en) 2020-06-24 2020-06-24 A composition for treating ovarian cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010588394.2A CN111603458B (en) 2020-06-24 2020-06-24 A composition for treating ovarian cancer

Publications (2)

Publication Number Publication Date
CN111603458A true CN111603458A (en) 2020-09-01
CN111603458B CN111603458B (en) 2022-12-16

Family

ID=72194204

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010588394.2A Active CN111603458B (en) 2020-06-24 2020-06-24 A composition for treating ovarian cancer

Country Status (1)

Country Link
CN (1) CN111603458B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104474093A (en) * 2014-11-26 2015-04-01 吉林大学 Traditional Chinese medicine for preventing and treating ovarian cancer and preparation method of traditional Chinese medicine
CN107049998A (en) * 2016-09-20 2017-08-18 南华大学附属第二医院 Application of the lycopene cis-isomer in treatment of ovarian cancer medicine is prepared

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104474093A (en) * 2014-11-26 2015-04-01 吉林大学 Traditional Chinese medicine for preventing and treating ovarian cancer and preparation method of traditional Chinese medicine
CN107049998A (en) * 2016-09-20 2017-08-18 南华大学附属第二医院 Application of the lycopene cis-isomer in treatment of ovarian cancer medicine is prepared

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKRAM JAMSHIDZADEH等: "Effect of Lycopene on Cyclophosphamide Induced Hemorrhagic Cystitis in Rats", 《IJMS》 *
兰健: "紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效", 《深圳中西医结合杂志》 *
康红钰等: "番茄红素对环磷酰胺治疗小鼠肉瘤Ｈ22的影响", 《郑州大学学报（医学版）》 *
熊方武等: "《中国临床药物大辞典. 化学药卷：全2卷》", 31 August 2018, 中国医药科技出版社 *

Also Published As

Publication number Publication date
CN111603458B (en) 2022-12-16

Similar Documents

Publication Publication Date Title
CN101342271B (en) Traditional Chinese medicine for treating qi-blood deficiency caused by tumour chemotherapy and preparation method thereof
CN102579763B (en) Externally applied traditional Chinese medicine composition for treating burns and scalds
GB2497926A (en) Drug treating high blood pressure
CN1305515C (en) Chinese medicinal powder and decoction composition for treating cancer
CN113209238A (en) Lotion for treating hand-foot syndrome caused by targeted medicament and preparation method thereof
CN111603458B (en) A composition for treating ovarian cancer
CN103784569B (en) A kind ofly treat Chinese medicine of hemorrhoid disease and preparation method thereof
CN108057089B (en) Moxibustion powder for treating chronic obstructive pulmonary disease and preparation method and application thereof
CN107812091B (en) Traditional Chinese medicine preparation for treating phlebitis caused by chemotherapy drugs and preparation method thereof
CN107158310A (en) A kind of chemotherapy adjuvant drug
CN105664053A (en) Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient
CN106822733B (en) Ointment for treating precancerous lesion of chronic atrophic gastritis and preparation method thereof
CN101152166B (en) Isoliquirtigenin gelling agent for treating hemorrhoids and method of preparing the same
CN115154568B (en) Traditional Chinese medicine composition for treating thyroid nodule and preparation method and application thereof
CN115887601B (en) A composition for treating hemorrhoid and its preparation method
CN113663036B (en) Traditional Chinese medicine composition for treating facial acne and preparation method thereof
CN1883659A (en) Chinese medicine for treating skin lesion and malignant tumor and application thereof
CN115475226A (en) Traditional Chinese medicine composition for treating non-small cell lung cancer with toxicity attenuation and synergism of docetaxel and cisplatin
CN114452369A (en) Traditional Chinese medicine composition for treating breast cancer
CN104906352A (en) Traditional Chinese medicine liquid for treating deficiency-fire flaring-up type infantile oral ulcer and preparation method thereof
CN118845906A (en) Compound tripterygium wilfordii composition, oral liquid and preparation method and application thereof
CN104998189A (en) Traditional Chinese medicine powder for treating infantile oral ulcer of wind-heat spleen type and preparation method thereof
CN113769027A (en) Traditional Chinese medicine formula for treating lung cancer
CN103316299B (en) Chinese medicine composition for treating primary liver cancer
CN110339330A (en) A kind of Chewable Tablets of Chinese traditional medicine for treating superficial gastritis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant